Elanco Animal Health Inc (ELAN) concluded trading on Wednesday at a closing price of $13.40, with 8.14 million shares of worth about $109.1 million changed hands on the day. On Wednesday the price saw a gain of about 1.67%. Currently the company’s common shares owned by public are about 496.46M shares, out of which, 491.95M shares are available for trading.
Stock saw a price change of 2.45% in past 5 days and over the past one month there was a price change of 40.90%. Year-to-date (YTD), ELAN shares are showing a performance of 10.65% which decreased to -18.74% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $8.02 but also hit the highest price of $18.80 during that period. The average intraday trading volume for Elanco Animal Health Inc shares is 5.64 million. The stock is currently trading 11.89% above its 20-day simple moving average (SMA20), while that difference is up 26.92% for SMA50 and it goes to 8.90% higher than SMA200.
Elanco Animal Health Inc (NYSE: ELAN) currently have 496.46M outstanding shares and institutions hold larger chunk of about 101.07% of that.
The stock has a current market capitalization of $6.66B and its 3Y-monthly beta is at 1.67. PE ratio of stock for trailing 12 months is 17.88, while it has posted earnings per share of $0.75 in the same period. Its PEG reads 2.96 and has Quick Ratio of 1.46 while making debt-to-equity ratio of 0.69. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ELAN, volatility over the week remained 1.84% while standing at 5.69% over the month.
Stock’s fiscal year EPS is expected to drop by -7.38% while it is estimated to increase by 13.62% in next year. EPS is likely to shrink at an annualized rate of 6.04% for next 5-years, compared to annual growth of 29.95% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by UBS on December 09, 2024 offering a Buy rating for the stock and assigned a target price of $18 to it. Coverage by Leerink Partners stated Elanco Animal Health Inc (ELAN) stock as a Market perform in their note to investors on December 02, 2024, suggesting a price target of $14 for the stock. On September 19, 2024, Morgan Stanley Downgrade their recommendations, while on January 05, 2024, Stifel Upgrade their ratings for the stock with a price target of $20. Stock get a Buy rating from Jefferies on December 19, 2023.
